CD276在头颈癌中的临床病理特征及预后价值：一项Meta分析

Clinicopathological features and prognostic value of CD276 expression in head and neck cancer: A meta-analysis.

作者信息

Su Hang, Li Ning, Chen Zitong, Hao Juanjuan, Zhang Fenghua

机构信息

Department of Thyroid and Breast Surgery, Hebei General Hospital, Shijiazhuang, China; Graduate School, North China University of Science and Technology, Tangshan, China.

Department of Thyroid and Breast Surgery, Hebei General Hospital, Shijiazhuang, China; Graduate School, Hebei Medical University, Shijiazhuang, China.

出版信息

Am J Otolaryngol. 2023 Nov-Dec;44(6):103968. doi: 10.1016/j.amjoto.2023.103968. Epub 2023 Jul 5.

DOI:10.1016/j.amjoto.2023.103968

PMID:37442085

Abstract

OBJECTIVE

We conducted a meta-analysis to assess the predictive value of CD276 expression in the clinicopathological features and prognosis of head and neck cancer.

METHODS

Pubmed, Embase, Cochrane library, Web of science, CNKI and Wanfang databases were searched for studies focused on the role of CD276 expression in the clinicopathological features and prognosis of head and neck cancer, published up to December 2022. STATA 14.0 were used to perform the meta-analysis.

RESULTS

A total of 8 eligible studies involving 1417 patients with head and neck cancer were included in this meta-analysis. The results showed that in terms of clinicopathological features, CD276 expression was related to gender [OR = 1.35, 95%CI = 1.01-1.82, P = 0.04], lymph node status [OR = 3.43, 95%CI = 1.96-5.98, P < 0.001] and TNM stage [OR = 2.54, 95%CI = 1.72-3.74, P < 0.001] of head and neck cancer patients, but not age [OR = 0.76, 95%CI = 0.52-1.11, P = 0.15] and tumor differentiation [OR = 1.39, 95%CI = 0.92-2.13, P = 0.12] . In terms of prognosis, CD276 expression is significantly associated with shorter overall survival [HR = 2.08, 95%CI = 1.22-3.56, P = 0.01] in head and neck cancer patients.

CONCLUSION

CD276 expression was significantly correlated with gender, lymph node status, TNM stage and poor prognosis in head and neck cancer patients and may be a new target for immunotherapy and a biomarker for predicting poor prognosis in head and neck cancer.

摘要

目的

我们进行了一项荟萃分析，以评估CD276表达在头颈癌临床病理特征和预后中的预测价值。

方法

检索了Pubmed、Embase、Cochrane图书馆、Web of science、CNKI和万方数据库，查找截至2022年12月发表的关于CD276表达在头颈癌临床病理特征和预后中作用的研究。使用STATA 14.0进行荟萃分析。

结果

本荟萃分析共纳入8项符合条件的研究，涉及1417名头颈癌患者。结果显示，在临床病理特征方面，CD276表达与头颈癌患者的性别[比值比（OR）=1.35，95%置信区间（CI）=1.01-1.82，P=0.04]、淋巴结状态[OR=3.43，95%CI=1.96-5.98，P<0.001]和TNM分期[OR=2.54，95%CI=1.72-3.74，P<0.001]相关，但与年龄[OR=0.76，95%CI=0.52-1.11，P=0.15]和肿瘤分化[OR=1.39，95%CI=0.92-2.13，P=0.12]无关。在预后方面，CD276表达与头颈癌患者较短的总生存期显著相关[风险比（HR）=2.08，95%CI=1.22-3.56，P=0.01]。